Cell Therapeutics to block hostile takeover with "poison pill" plan

12/28/2009 | Bloomberg Businessweek · American City Business Journals

Cell Therapeutics has resorted to a shareholder-rights plan in an effort to keep potential buyers from acquiring the company without providing a fair takeover bid for its stockholders. The "poison pill" plan comes as the company awaits FDA approval of pixantrone, its drug candidate for aggressive non-Hodgkin's lymphoma.

View Full Article in:

Bloomberg Businessweek · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL